Impact of the Inflation Reduction Act on drug development and patients: an interview with Jason Spangler, Innovation and Value Initiative

29 Jun 2023

Written by Jason Spangler (Innovation and Value Initiative)

Events coverage Health economics Health policy Health technology assessment Interviews ISPOR Market access Medical devices, pharmaceuticals and vaccines Value assessment

Photo of Jason Spangler, of Innovation and Value Initiative discussing the impact of the Inflation Reduction Act on drug development and patients

As we continue to delve into the impact of the Inflation Reduction Act (IRA) on the landscape of health care in the US, in this interview we hear from Jason Spangler, MD, MPH, FACPM, CEO of the Innovation and Value Initiative (IVI) to understand the potential effect this landmark legislation may have on drug development and patients. This interview is based on a session at the recent ISPOR 2023 meeting on the topic, ‘Considering the Impact of the Inflation Reduction Act on Drug Development and Patients’. Please could you introduce yourself and your organization? I’ve worked in the professional health...